← Feed

$SPRO

2 theses
bullish 100%neutral 0%bearish 0%
Avg return (3m)
—
Win rate (3m)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 11, 4:30 PM ET
$SPROr/pennystocksGeneral Discussionbullish
u/GeneralZello · 51d ago3 prior · 0% at 3mo
Long 11,000 shares of SPRO

SPRO Spero Therapeutics FDA approval and then drops? Cheaper buyout?

SPRO is undervalued following FDA approval of Utebzi (marketed via GSK partnership with estimated $1B+ sales potential) and a $1.1B milestone deal for SP001. Despite strong catalysts, the stock has declined post-approval, making it a buyout candidate trading well below intrinsic value.

At post $1.16Now $1.13-2.6% since postedas of Sep 11, 4:30 PM ET
1d+2.6%
3d+2.6%
1w+3.4%
1m+5.2%
3m—
6m—
1y—
original post →
$SPROr/pennystocksGeneral Discussionbullish
u/Weekly-Barracuda-494 · 60d ago1 prior · awaiting results

Spero Therapeutics Changing focus

Spero Therapeutics monetized GSK royalties to fund an asset acquisition from Innovent Biologics, positioning the company to run Phase 2/3 trials on a new antibody program with sufficient capital on hand and up to $326M in milestone payments from GSK, potentially avoiding dilution.

At post $1.70Now $1.13-33.5% since postedas of Sep 11, 4:30 PM ET
original post →

End of results.